Document Type

Plan B - Open Access

Award Date

2020

Department

Biology and Microbiology

First Advisor

Greg Heiberger

Abstract

Irritable bowel syndrome with constipation (IBS-C) affects a large proportion of the population. It decreases quality of life for the patient both physically and mentally. Patients report higher levels of mental health issues and other gastrointestinal maladies compared to the normal population, in addition to an IBS diagnosis. Patients have increased healthcare visits and costs, raising insurance rates for all, and also results in more missed time from work. There are limited treatments available for IBS-C, and medicinal and non-medicinal modalities are differentially prescribed to patients throughout the country. Recently, serotonin has emerged as a key mediator of normal gut function, and thus, of IBS dysfunction. This chemical is implicated in physiological processes throughout the body, and serves as a key focus of IBS treatment. Current knowledge of IBS-C, treatments, and differences in care plans based on geography are explored in this review.

Format

application/pdf

Number of Pages

26

Publisher

South Dakota State University

Rights

Copyright © 2020 Meghan Schenk

Share

COinS